Schedule 3  Notifiable low risk dealings in relation to a GMO (regulations 12 and 13)

Part 1  Notifiable low risk dealings suitable for at least physical containment level 1

1.1 Kinds of dealings suitable for at least physical containment level 1

The following kinds of notifiable low risk dealings must be undertaken, unless paragraph 13 (2) (c) or 13 (3) (b) applies, in facilities certified to at least physical containment level 1 and that are appropriate for the dealings:

(a) a dealing involving a genetically modified laboratory guinea pig, a genetically modified laboratory mouse, a genetically modified laboratory rabbit or a genetically modified laboratory rat, unless:

(i) an advantage is conferred on the animal by the genetic modification; or

(ii) the animal is capable of secreting or producing an infectious agent as a result of the genetic modification;

(c) a dealing involving a replication defective vector derived from Human adenovirus or Adeno associated virus in a host mentioned in item 4 of Part 2 of Schedule 2, if the donor nucleic acid:

(i) cannot restore replication competence to the vector; and

(ii) does not:

(A) confer an oncogenic modification in humans; or
Part 2 Notifiable low risk dealings suitable for at least physical containment level 2 or 3

Note Because of subregulation 12 (1), a dealing mentioned in this Part is not a notifiable low risk dealing if it is also a dealing of a kind mentioned in Part 3.

2.1 Kinds of dealings suitable for at least physical containment level 2

The following kinds of notifiable low risk dealings must be undertaken, unless paragraph 13 (2) (c) or 13 (3) (b) applies, in facilities certified to at least physical containment level 2 and that are appropriate for the dealings:

(a) a dealing involving whole animals (including non-vertebrates) that:
   (i) involves genetic modification of the genome of the oocyte or zygote or early embryo by any means to produce a novel whole organism; and
   (ii) does not involve any of the following:
      (A) a genetically modified laboratory guinea pig;
      (B) a genetically modified laboratory mouse;
      (C) a genetically modified laboratory rabbit;
      (D) a genetically modified laboratory rat;
      (E) a genetically modified Caenorhabditis elegans;

(aa) a dealing involving a genetically modified laboratory guinea pig, a genetically modified laboratory mouse, a genetically modified laboratory rabbit, a genetically modified laboratory rat or a genetically modified Caenorhabditis elegans, if:
   (i) the genetic modification confers an advantage on the animal; and
   (ii) the animal is not capable of secreting or producing an infectious agent as a result of the genetic modification;